Cargando…

SARS-CoV-2 cell entry and targeted antiviral development

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic coronavirus disease 2019 (COVID-19), which threatens human health and public safety. In the urgent campaign to develop anti-SARS-CoV-2 therapies, the initial entry step is one of the most appealing ta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zinuo, Du, Ruikun, Galvan Achi, Jazmin M., Rong, Lijun, Cui, Qinghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117542/ https://www.ncbi.nlm.nih.gov/pubmed/34002130 http://dx.doi.org/10.1016/j.apsb.2021.05.007

Ejemplares similares

Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro)
por: Du, Ruikun, et al.
Publicado: (2021)

Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases
por: Chen, Zinuo, et al.
Publicado: (2021)

Comparative analyses of small molecule and antibody inhibition on glycoprotein‐mediated entry of Měnglà virus with other filoviruses
por: Cooper, Laura, et al.
Publicado: (2022)

Competitive Cooperation of Hemagglutinin and Neuraminidase during Influenza A Virus Entry
por: Du, Ruikun, et al.
Publicado: (2019)

Lignans and Their Derivatives from Plants as Antivirals
por: Cui, Qinghua, et al.
Publicado: (2020)

Small Molecule Inhibitors of Influenza Virus Entry
por: Chen, Zhaoyu, et al.
Publicado: (2021)

Revisiting influenza A virus life cycle from a perspective of genome balance
por: Du, Ruikun, et al.
Publicado: (2022)

A Parallel Phenotypic Versus Target-Based Screening Strategy for RNA-Dependent RNA Polymerase Inhibitors of the Influenza A Virus
por: Zhao, Xiujuan, et al.
Publicado: (2019)

Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus
por: Cui, Qinghua, et al.
Publicado: (2018)

Expanding the tolerance of segmented Influenza A Virus genome using a balance compensation strategy
por: Zhao, Xiujuan, et al.
Publicado: (2022)

Identification of the SARS-unique domain of SARS-CoV-2 as an antiviral target
por: Qin, Bo, et al.
Publicado: (2023)

Flu Universal Vaccines: New Tricks on an Old Virus
por: Du, Ruikun, et al.
Publicado: (2020)

Identification of a New Region of SARS-CoV S Protein Critical for Viral Entry
por: Guo, Ying, et al.
Publicado: (2009)

Cell entry by SARS-CoV-2
por: Peng, Ruchao, et al.
Publicado: (2021)

Clotting and SARS-CoV-2 entry
por: Hofer, Ursula
Publicado: (2022)

In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals
por: Şimşek, Yusuf, et al.
Publicado: (2021)

Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor
por: Cui, Qinghua, et al.
Publicado: (2018)

Current therapy and development of therapeutic agents for lung cancer
por: Wang, Zilai, et al.
Publicado: (2022)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development
por: Lv, Zongyang, et al.
Publicado: (2022)

Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1
por: Yang, Jing, et al.
Publicado: (2021)

Antiviral Activity of Two Marine Carotenoids against SARS-CoV-2 Virus Entry In Silico and In Vitro
por: Yim, Sung-Kun, et al.
Publicado: (2021)

Targeting Spike Glycans to Inhibit SARS-CoV2 Viral Entry
por: Guseman, Alex J., et al.
Publicado: (2022)

Targeting spike glycans to inhibit SARS-CoV2 viral entry
por: Guseman, Alex J., et al.
Publicado: (2023)

A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase
por: Li, Ping, et al.
Publicado: (2018)

TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2
por: Wang, Yinfang, et al.
Publicado: (2021)

Cell entry mechanisms of SARS-CoV-2
por: Shang, Jian, et al.
Publicado: (2020)

SARS-CoV-2, Early Entry Events
por: Chambers, James P., et al.
Publicado: (2020)

Mechanisms of SARS-CoV-2 entry into cells
por: Jackson, Cody B., et al.
Publicado: (2021)

SARS-CoV-2 RNA polymerase as target for antiviral therapy
por: Buonaguro, Luigi, et al.
Publicado: (2020)

Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry
por: Palacios-Rápalo, Selvin Noé, et al.
Publicado: (2021)

Targeting RNA G-quadruplex with repurposed drugs blocks SARS-CoV-2 entry
por: Tong, Qiyu, et al.
Publicado: (2023)

SARS-CoV-2 Antiviral Therapy
por: Tao, Kaiming, et al.
Publicado: (2021)

Computational designing of a peptide that potentially blocks the entry of SARS-CoV, SARS-CoV-2 and MERS-CoV
por: V. K., Priya, et al.
Publicado: (2021)

Macromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2
por: Groß, Rüdiger, et al.
Publicado: (2022)

Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition
por: Sanna, Vanna, et al.
Publicado: (2022)

Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry
por: Qing, Enya, et al.
Publicado: (2022)

Targeting the entry step of SARS-CoV-2: a promising therapeutic approach
por: Li, Jing, et al.
Publicado: (2020)

SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention
por: Mahmoud, Ismail Sami, et al.
Publicado: (2020)

Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein
por: Chen, Yuliu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ro4in4dlejgpqjpnvc7etl6bt9